We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simplified Assay Quantifies Circulating Activated Protein C

By LabMedica International staff writers
Posted on 24 Aug 2016
The protein C (PC) anticoagulant pathway plays a crucial role in the regulation of fibrin formation by inactivating the pro-coagulant cofactors factor Va and factor VIIIa.

The physiological relevance of PC in the regulation of blood coagulation arises from the description of increased risk of venous thromboembolism (VTE) associated with both hereditary PC deficiency and low circulating activated protein C (APC) levels. More...
Available assays for circulating levels of APC are either time-consuming or difficult to use in a routine laboratory, or have a detection limit above normal levels.

Scientists at the Instituto de Investigación Sanitaria La Fe (Valencia, Spain) developed a simplified assay that measures both the in vivo free APC and the in vivo APC complexed to PC inhibitor (PCI). They measured APC levels, with both assays, in 339 plasma samples, 165 from patients with venous thromboembolism (VTE) and 174 from healthy individuals.

The PCI antigens were determined and PCI concentration was expressed in nM, assuming a molecular weight for PCI of 57,000 and a concentration of plasma PCI, in pooled normal plasma, of 87.7 nM. APC: PCI complexes were determined by a sandwich enzyme-linked immunosorbent assay (ELISA). Microplates were coated with a monoclonal antibody to PC and complexes were detected with peroxidase-labeled polyclonal antibodies to PCI. APC concentration in the complex is expressed in nM, assuming a molecular weight of APC of 57,000.

The investigators found that the mean APC level in the 339 samples was 0.038 ± 0.010 nM, using a previous assay that measures only the in vivo APC level, and 0.041 ± 0.010 nM with the present new assay. The mean APC level in VTE patients was 0.034 ± 0.009 nM (previous assay) and 0.037 ± 0.009 nM (new assay), significantly lower than those in controls. In both groups there was a significant correlation between the levels obtained by the two assays.

The authors concluded that their results show that both assays are equivalent, and confirm that the APC level is lower in VTE patients than in healthy individuals. Therefore, the new simplified assay, which measures the sum of circulating free APC and APC complexed to PCI, may be used to estimate the level of circulating APC, and will allow its use in routine laboratories. The study was published on August 1, 2016, in the journal Clinica Chimica Acta.

Related Links:
Instituto de Investigación Sanitaria La Fe



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.